Updates
Please find attached herewith an updated Investors' Presentation for your kind ready reference.22-03-2017
22-03-2017
Updates
We hereby inform that the Company has designated Dr. Sharvil P. Patel, the Deputy Managing Director as a Joint Managing Director. However, there is no change in other terms of his appointment.15-03-2017
USFDA nod for Zydus' muscle relaxant
Cadila Healthcare Ltd (Zydus Cadila) aid it has received final approval from the USFDA to market Tizanidine hydrochloride capsules, USP in strengths of 2mg, 4mg and 6mg. The drug, which is a muscle...09-03-2017
Zydus receives USFDA nod for muscle relaxant drug
Cadila Healthcare Ltd (Zydus Cadila), on Wednesday, said it has received final approval from the USFDA to market Tizanidine hydrochloride capsules, USP in strengths of 2mg, 4mg and 6mg. The drug,...08-03-2017
Zydus Cadila receives final approval from the US FDA for Tizanidine Hydrochloride capsules
Cadila Healthcare has received final approval from the US FDA to sell Tizanidine Hydrochloride capsules in the US. Estimated sales for these capsules in the US over the last twelve months was $58.6 million. The company will be manufacturing these capsules at the SEZ facility in Ahmedabad.08-03-2017
Press Release
We enclose herewith a copy of press release dated March 8, 2017, titled Zydus Cadila receives final approval from the USFDA for Tizanidine Hydrochloride Capsules.08-03-2017
Outcome of Board Meeting
Pursuant to SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015, we inform that the Board of Directors at their meeting held today approved the payment of interim dividend at Rs.3.20/- per equity share on 1,023,742,600 Equity Share of Rs.1/- each for the Financial Year 2016-17. The Board of Directors in above meeting also fixed March 17, 2017 as the Record Date to ascertain the list of members entitled to receive the interim...07-03-2017
Press Release
We enclose herewith a copy of press release dated March 7, 2017, titled Zydus announces settlement with Supernus on Trokendi XR (topiramate) extended-release capsules. The contents of the press release give full details. Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.07-03-2017
US regulator observations at Baddi unit may not effect Cadila
Ahmedabad-headquartered Cadila Healthcare has today informed the Bombay Stock Exchange (BSE) that its Baddi plant has received three observations from the US Food and Drug Administration (USFDA) related to a pre-approval inspection (PAI) for a specific product filed. While the company's shares on the BSE tanked 1.76 per cent in day's trade, analysts say this would have no immediate impact on revenues. Cadila Healthcare said in its statement that the USFDA had inspected its formulations manufacturing facility at Baddi from February 20 to March 1 and at the end of the inspection, there were three observations given under form 483. "All these three observations are related to Pre-Approval Inspection (PAI) for a specific product filed. This product is yet to be manufactured or marketed in the US. The company is already in the process of responding to the PAI observations. Apart from above product related observations, there are no observations related to cGMP practices," it said.As per...03-03-2017
Cadila Healthcare facility in Baddi receives three observations from FDA
The USFDA inspected Cadila Healthcare's formulations manufacturing facility at Baddi over the last ten days, starting February 20th. At the end of the inspection, there were 3 observations given by the FDA to the facility under form 483. All three observations, Cadila says, are related to Pre-Approval Inspection (PAI) "for a specific product filed". This product is yet to be manufactured or marketed in the US, but is pending approval with the FDA.02-03-2017